

**GOVERNMENT OF INDIA
MINISTRY OF HEALTH AND FAMILY WELFARE
DEPARTMENT OF HEALTH AND FAMILY WELFARE**

**RAJYA SABHA
UNSTARRED QUESTION NO. 1403
TO BE ANSWERED ON 14th MARCH, 2017**

STEPS TO PROMOTE INDIAN PHARMACEUTICAL COMPANIES

1403. SHRI MD. NADIMUL HAQUE:

Will the Minister of **HEALTH AND FAMILY WELFARE** be pleased to state:

- (a) how will Make in India benefit Indian pharmaceutical companies, the details thereof;
- (b) what are the steps taken to promote invention and innovation in medicine manufacturing in the country and the details thereof;
- (c) what steps are taken to promote private Indian companies to invest more on research and development of essential medicines and the details thereof; and
- (d) what are the concessions and benefits provided to them and the details thereof?

**ANSWER
THE MINISTER OF STATE IN THE MINISTRY OF HEALTH AND
FAMILY WELFARE
(SHRI FAGGAN SINGH KULASTE)**

(a) to (c): 'Make In India', in so far as Pharma sector is concerned, aims to make Indian pharma industry more competitive. Indian pharma sector is currently valued at around Rs. 2 lakh crore. With changes in regulatory framework leading to ease of doing business, emphasis on enforcement of quality through better implementation of Good Manufacturing Practices, Good Laboratory Practices, and better facilities for testing and analysis in laboratory, etc., the Indian pharma sector would be able to provide quality medicines at reasonable price and, consequently, its share in the global pharma trade will increase. Various measures have also been taken to make the process of approval of clinical trials and clinical research more transparent, objective and predicable. These measures will lead to increased activities in research and development and the availability of more new medicines.

(d): The Government is providing financial support for research and development through Drugs & Pharmaceuticals Research Programme (DPRP) run by the Department of Science & Technology. The companies undertaking Research & Development activities are also provided income tax benefits. The Drugs (Prices Control) Order, 2013, Para-32(iii) provides exemptions from price control to a manufacturer producing a new drug involving a new delivery system developed through indigenous Research and Development for a period of five years from the date of its market approval in India.'